Pacific Biosciences Of California (PACB) Profit After Tax (QoQ) (2010 - 2026)
Pacific Biosciences Of California (PACB) Profit After Tax (QoQ) (2010 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 182.61 Bn | 175.32 Bn | 6.27 Bn |
| 2 | Stryker | 128.95 Bn | 126.07 Bn | 3.81 Bn |
| 3 | Medtronic | 108.22 Bn | 99.00 Bn | 6.41 Bn |
| 4 | Boston Scientific | 68.29 Bn | 66.84 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 48.30 Bn | 44.63 Bn | 1.29 Bn |
| 6 | Dexcom | 28.31 Bn | 27.19 Bn | 750.30 Mn |
| 7 | GE HealthCare Technologies | 28.03 Bn | 25.75 Bn | 1.98 Bn |
| 8 | Smith & Nephew | 27.01 Bn | 26.43 Bn | - |
| 9 | Koninklijke Philips | 24.04 Bn | 20.91 Bn | 2.07 Bn |
| 10 | Pacific Biosciences Of California | 417.44 Mn | 141.48 Mn | 12.84 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 79.50% |
| Dec 31, 2025 | -6.65% |
| Sep 30, 2025 | -33,103.51% |
| Jun 30, 2025 | -178.05% |
| Mar 31, 2025 | -103.95% |
| Dec 31, 2024 | -50.05% |
| Sep 30, 2024 | 101.20% |
| Jun 30, 2024 | -120.22% |
| Mar 31, 2024 | 1.57% |
| Dec 31, 2023 | -21.11% |
| Sep 30, 2023 | 5.46% |
| Jun 30, 2023 | 20.66% |
| Mar 31, 2023 | -4.30% |
| Dec 31, 2022 | -8.50% |
| Sep 30, 2022 | -8.94% |
| Jun 30, 2022 | 15.51% |
| Mar 31, 2022 | -21.88% |
| Jun 30, 2021 | 53.11% |
| Mar 31, 2021 | -216.56% |
| Dec 31, 2020 | 416.41% |